Breaking News Instant updates and real-time market news.

HALO

Halozyme

$13.18

0.12 (0.92%)

, RHHBY

Roche

$31.49

-0.06 (-0.19%)

07:09
09/14/17
09/14
07:09
09/14/17
07:09

Halozyme licences new Enhanze target for $30M upfront payment from Roche

Halozyme (HALO) licensed its Enhanze drug-delivery technology to Roche (RHHBY) for exclusive development of an undisclosed therapeutic target. Halozyme will receive an initial $30M with the potential to earn additional payments of up to $160M subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive tiered, mid-single digit royalties on sales of commercialized products. The Halozyme/Roche relationship dates back to the original global collaboration and licensing agreement for the ENHANZE technology signed in 2006.

HALO

Halozyme

$13.18

0.12 (0.92%)

RHHBY

Roche

$31.49

-0.06 (-0.19%)

  • 25

    Sep

  • 30

    Nov

HALO Halozyme
$13.18

0.12 (0.92%)

04/17/17
BMOC
04/17/17
INITIATION
Target $14
BMOC
Market Perform
Halozyme initiated with a Market Perform at BMO Capital
BMO Capital initiated Halozyme with a Market Perform and a $714 price target.
03/30/17
DBAB
03/30/17
NO CHANGE
Target $17
DBAB
Buy
Halozyme price target raised to $17 from $15 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme to $17 saying the positive, "unanimous and uncontroversial" FDA Advisory Committee meeting for Rituxan-SC highlights the "strong potential" for the broader Enhanze platform. The analyst reiterates a Buy rating on the shares.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
01/05/17
PIPR
01/05/17
NO CHANGE
Target $20
PIPR
Overweight
Halozyme price target raised to $20 after pancreas cancer data at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target on Halozyme to $20 from $18, saying the company's "encouraging" Phase 2 data for its pancreas cancer combination treatment reduce the risk to the ongoing Phase 3 program for the combo. Duncan keeps an Overweight rating on Halozyme.
RHHBY Roche
$31.49

-0.06 (-0.19%)

09/12/17
COWN
09/12/17
NO CHANGE
COWN
Cowen says cervical cancer recommendations a risk for Hologic, Becton Dickinson
Cowen analyst Doug Schenkel noted that the US Preventive Services Task Force recently released a draft recommendation on cervical cancer screening, which no longer recommends cotesting with both an HPV assay and cytology, which would be a negative for Hologic (HOLX) and Becton Dickinson (BDX) if the draft is implemented. If the draft is implemented, it is likely a positive for Roche (RHHBY), the only vendor with a primary screening HPV assay that is FDA approved, added Schenkel. However, the final recommendation statement can be materially different from the draft, he said.
09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
08/23/17
WBLR
08/23/17
INITIATION
Target $107
WBLR
Outperform
AveXis initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started AveXis (AVXS) with an Outperform rating and $107 fair value estimate, noting that the company's Phase I data for AVXS-101have continued to show a meaningful benefit in spinal muscular atrophy type 1. The analyst, who thinks AveXis has a high probability of receiving guidance for a potential regulatory filing following the company's end-of-Phase I meeting with the FDA, said AveXis could become an acquisition target within the next 12-18 months. If so, an acquisition price could be in the range of $150-$160 per share, with Roche (RHHBY) and Biogen (BIIB) possible suitors, Prasad tells investors.
08/08/17
JEFF
08/08/17
NO CHANGE
Target $75
JEFF
Buy
FibroGen price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for FibroGen (FGEN) shares to $75 saying "significant value creation should occur now" after the company reported positive Phase II idiopathic pulmonary fibrosis lung data for FG-3019. The analyst believes the $5B market capitalization implied by his new price target could prove conservative. InterMune had comparable data and was acquired by Roche (RHHBY) for $8B, Yee tells investors in a research note. The analyst reiterates a Buy rating on FibroGen. The stock in premarket trading is up 59%, or $19.60, to $53.00.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

18:17
09/19/17
09/19
18:17
09/19/17
18:17
Hot Stocks
Bed Bath & Beyond says biggest component in drop of FY17 EPS view is operations »

Company dropped its FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CPRT

Copart

$32.54

-0.32 (-0.97%)

18:11
09/19/17
09/19
18:11
09/19/17
18:11
Earnings
Copart reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STLD

Steel Dynamics

$33.83

0.03 (0.09%)

18:04
09/19/17
09/19
18:04
09/19/17
18:04
Earnings
Steel Dynamics sees Q3 adjusted EPS 63c-67c, consensus 70c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XBKS

Xenith Bankshares

$29.96

0.42 (1.42%)

17:58
09/19/17
09/19
17:58
09/19/17
17:58
Hot Stocks
Treasury exits stake in Xenith Bankshares »

Xenith Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Periodicals
Breaking Periodicals news story on Bristol-Myers »

Times:NHS will supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

BBBY

Bed Bath & Beyond

17:54
09/19/17
09/19
17:54
09/19/17
17:54
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

DESP

Despegar.com

17:52
09/19/17
09/19
17:52
09/19/17
17:52
Syndicate
Despegar.com 12.7M share IPO priced at $26.00 »

The IPO priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WAC

Walter Investment

$0.65

0.186 (40.09%)

17:50
09/19/17
09/19
17:50
09/19/17
17:50
Hot Stocks
Walter Investment says Barclays to increase financing available »

On September 13, Walter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49
Initiation
CymaBay initiated  »

CymaBay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

17:46
09/19/17
09/19
17:46
09/19/17
17:46
Hot Stocks
Bed Bath & Beyond sees net drop in Bed Bath & Beyond stores in FY17 »

Says rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

EVH

Evolent Health

$15.65

-0.8 (-4.86%)

17:45
09/19/17
09/19
17:45
09/19/17
17:45
Initiation
Evolent Health initiated  »

Evolent Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPL

Buckeye Partners

$56.33

0.64 (1.15%)

17:44
09/19/17
09/19
17:44
09/19/17
17:44
Syndicate
Buckeye Partners announces $210M in limited partnership unit sales »

Buckeye Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$91.03

0.87 (0.96%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
Ralph Lauren initiated  »

Ralph Lauren initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

PVH

PVH Corp.

$127.47

-0.54 (-0.42%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Initiation
PVH Corp. initiated  »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

, ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

17:43
09/19/17
09/19
17:43
09/19/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Gemphire…

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

FDX

FedEx

$216.00

0.92 (0.43%)

ADBE

Adobe

$156.60

0.83 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 22

    Oct

KORS

Michael Kors

$46.18

1.53 (3.43%)

17:42
09/19/17
09/19
17:42
09/19/17
17:42
Initiation
Michael Kors initiated  »

Michael Kors initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$39.23

-0.75 (-1.88%)

17:42
09/19/17
09/19
17:42
09/19/17
17:42
Initiation
L Brands initiated  »

L Brands initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBI

Hanesbrands

$24.71

-0.02 (-0.08%)

17:41
09/19/17
09/19
17:41
09/19/17
17:41
Initiation
Hanesbrands initiated  »

Hanesbrands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

17:41
09/19/17
09/19
17:41
09/19/17
17:41
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

GIII

G-III Apparel

$29.15

-0.26 (-0.88%)

17:41
09/19/17
09/19
17:41
09/19/17
17:41
Initiation
G-III Apparel initiated  »

G-III Apparel initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

-0.12 (-0.30%)

17:40
09/19/17
09/19
17:40
09/19/17
17:40
Initiation
Coach initiated  »

Coach initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$27.94

0.04 (0.14%)

17:40
09/19/17
09/19
17:40
09/19/17
17:40
Initiation
Gap initiated  »

Gap initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFR

Starwood Waypoint Homes

$36.97

0.35 (0.96%)

17:37
09/19/17
09/19
17:37
09/19/17
17:37
Hot Stocks
Starwood Waypoint Homes gets subpoena from SEC requesting documents »

Starwood Waypoint Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GVA

Granite Construction

$56.51

-0.56 (-0.98%)

17:36
09/19/17
09/19
17:36
09/19/17
17:36
Hot Stocks
Granite Construction awarded $23M contract in San Diego »

Granite Construction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

17:34
09/19/17
09/19
17:34
09/19/17
17:34
Earnings
Bed Bath & Beyond sees FY17 revenue flat, consensus $12.47B »

Sees FY17 SSS down in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.